XNASPASG
Market cap41mUSD
Jan 10, Last price
0.67USD
1D
1.67%
1Q
11.67%
IPO
-96.88%
Name
Passage Bio Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.97%
Rev. gr., 5y
%
Revenues
0k
Net income
-102m
L-25.42%
CFO
-78m
L-33.79%
Earnings
Mar 03, 2025
Profile
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 106,720 | 139,073 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (106,720) | (139,073) | ||||
NOPBT Margin | ||||||
Operating Taxes | 731 | |||||
Tax Rate | ||||||
NOPAT | (106,720) | (139,804) | ||||
Net income | (102,062) -25.42% | (136,856) -28.53% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 135 | 737 | ||||
BB yield | -0.24% | -0.98% | ||||
| Debt | ||||||
Debt current | 6,746 | 3,275 | ||||
Long-term debt | 49,215 | 50,939 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (58,333) | (135,396) | ||||
| Cash flow | ||||||
Cash from operating activities | (78,264) | (118,210) | ||||
CAPEX | (146) | (5,274) | ||||
Cash from investing activities | 65,237 | 25,199 | ||||
Cash from financing activities | 135 | (1) | ||||
FCF | (96,635) | (158,236) | ||||
| Balance | ||||||
Cash | 114,294 | 189,610 | ||||
Long term investments | ||||||
Excess cash | 114,294 | 189,610 | ||||
Stockholders' equity | (594,506) | (493,367) | ||||
Invested Capital | 735,456 | 721,840 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 54,743 | 54,429 | ||||
Price | 1.01 -26.81% | 1.38 -78.27% | ||||
Market cap | 55,291 -26.39% | 75,112 -77.83% | ||||
EV | (3,042) | (60,284) | ||||
EBITDA | (102,999) | (135,394) | ||||
EV/EBITDA | 0.03 | 0.45 | ||||
Interest | 2,269 | |||||
Interest/NOPBT | ||||||